BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32770086)

  • 1. Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
    Chowdhury O; O'Sullivan J; Barkas N; Wang G; Buck G; Hamblin A; Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; Ribrag V; Schiller G; Vannucchi AM; Zhou D; McMullin MF; Zhong J; Gale RP; Mead AJ;
    Leukemia; 2021 Apr; 35(4):1197-1202. PubMed ID: 32770086
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
    Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; McMullin MF; Ribrag V; Schiller G; Vannucchi AM; Zhou D; Reiser D; Zhong J; Gale RP
    Leukemia; 2017 Apr; 31(4):896-902. PubMed ID: 27773929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
    Schlenk RF; Stegelmann F; Reiter A; Jost E; Gattermann N; Hebart H; Waller C; Hochhaus A; Platzbecker U; Schafhausen P; Blau IW; Verbeek W; Heidel FH; Werner M; Kreipe H; Teleanu V; Benner A; Döhner H; Grießhammer M; Döhner K
    Leukemia; 2017 Apr; 31(4):889-895. PubMed ID: 27774990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis.
    Bartoszko J; Panzarella T; Lau A; Schimmer A; Schuh A; Shanavas M; Yee K; Gupta V
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e151-6. PubMed ID: 26566925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
    Tefferi A; Hudgens S; Mesa R; Gale RP; Verstovsek S; Passamonti F; Cervantes F; Rivera C; Tencer T; Khan ZM
    Clin Ther; 2014 Apr; 36(4):560-6. PubMed ID: 24636526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].
    Edahiro Y; Gotoh A; Inano T; Tsutsui M; Tsukune Y; Yasuda H; Komatsu N
    Rinsho Ketsueki; 2018; 59(3):323-325. PubMed ID: 29618692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase-2 trial of low-dose pomalidomide in myelofibrosis.
    Begna KH; Mesa RA; Pardanani A; Hogan WJ; Litzow MR; McClure RF; Tefferi A
    Leukemia; 2011 Feb; 25(2):301-4. PubMed ID: 21052089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
    Daver N; Shastri A; Kadia T; Quintas-Cardama A; Jabbour E; Konopleva M; O'Brien S; Pierce S; Zhou L; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2013 Nov; 37(11):1440-4. PubMed ID: 23890523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research status and challenges of advanced myeloproliferative neoplasms].
    Bai J; Zhang YH; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3603-3607. PubMed ID: 38018058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
    Duan M; Zhou D
    Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
    [No Abstract]   [Full Text] [Related]  

  • 12. Allogeneic haematopoietic stem cell transplantation for primary myelofibrosis and myelofibrosis evolved from other myeloproliferative neoplasms.
    Tamari R; Castro-Malaspina H
    Curr Opin Hematol; 2015 Mar; 22(2):184-90. PubMed ID: 25635756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease.
    Gilbert HS
    Prog Clin Biol Res; 1984; 154():3-17. PubMed ID: 6382299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloproliferative Neoplasms.
    Spivak JL
    N Engl J Med; 2017 Jun; 376(22):2168-2181. PubMed ID: 28564565
    [No Abstract]   [Full Text] [Related]  

  • 15. Practical management of the haemorrhagic complications of myeloproliferative neoplasms.
    Jones E; Dillon B; Swan D; Thachil J
    Br J Haematol; 2022 Nov; 199(3):313-321. PubMed ID: 35724983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
    Liu YC; Illar GM; Bailey NG
    J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelofibrosis in myeloproliferative disorders.
    Srinivasan U; Talvalkar GV; Advani SH
    Indian J Cancer; 1978 Sep; 15(3):37-43. PubMed ID: 294411
    [No Abstract]   [Full Text] [Related]  

  • 18. A case of a primary myelofibrosis with progression and related literature review of progression phase genetics.
    Chen D; Fuda F; Weinberg O
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():78-81. PubMed ID: 34288445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathophysiology of and therapy for primary myelofibrosis].
    Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1724-32. PubMed ID: 17802728
    [No Abstract]   [Full Text] [Related]  

  • 20. When to initiate treatment in myelofibrosis.
    Harrison C
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):934-937. PubMed ID: 27930645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.